AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- Results of a study in mice suggest nasal immunization with heat shock proteins could be a new approach to treating atherosclerosis.
According to researchers, "Increasing evidence supports the involvement of inflammation and immunity in atherogenesis as well as the role of autoimmunity to heat shock proteins (HSPs) in the progression of atherosclerosis. Mucosal administration of autoantigens decreases organ-specific inflammation and disease in several models of autoimmunity (diabetes, arthritis, and encephalomyelitis) and is also being tested in human clinical trials."
R. Maron and colleagues, Brigham and Women's Hospital, Boston, Massachusetts, "examined the effect of nasal or oral administration of mycobacterial HSP-65 on atherosclerotic lesion formation in mice lacking the receptor for LDL [low density lipoprotein] that were maintained on a high-cholesterol diet." They reported their findings in the journal Circulation.
"Animals were nasally or orally treated for 1 week with HSP-65, and a high-cholesterol diet was started after the last treatment. The mice were mucosally treated once a week for 8 or 12 weeks, at which time pathological analysis was performed," wrote Maron and coauthors (Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation, ...
Source: HighBeam Research, Nasal immunization with heat shock proteins has therapeutic potential.